

Independent Auditor's Report

To: Suresh Surana & Associates LLP

In accordance with your *Group Reporting Instructions* dated 30 march, 2021, we have audited, for purposes of your audit of the consolidated financial statements of Glenmark Group, the accounting statements of Glenmark Farmacêutica Ltda as of 31 march 2021 and for the year then ended of the accompanying accounting statements of Glenmark Farmacêutica Ltda. This accounting statements has been prepared solely to enable Glenmark Group to prepare its consolidated financial statements.

Management's Responsibility for accounting statements

Management is responsible for the preparation and fair presentation of the accounting statements in accordance and in accordance with accounting practices adopted in Brazil and international standards and the group's accounting policies for inclusion in the consolidated financial statements of Glenmark Group and is intended solely for that purpose. Management is also responsible for such internal controls as necessary to enable the preparation and fair presentation of component financial information that is free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on the accounting statements based on our audit. We conducted our audit in accordance with in accordance with Brazilian and international auditing standards, adapted as necessary based on your instructions for purpose of your audit of the consolidated financial statements of Glenmark Group.

Brazilian and international auditing standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the accounting statements is free from material misstatement. As requested by Suresh Surana & Associates LLP, we planned and performed our audit using the materiality level specified in the Group Reporting Instructions, which is different than the materiality level that we would have used had we been designing the audit to express an opinion on the financial information of the component alone.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the component financial information. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the component financial information, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the component financial information to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the accounting statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion. The conclusions reached in forming our opinion are based on the component materiality level specified by you in the context of the audit of the consolidated financial statements of the group.



Opinion

In our opinion, the afore mentioned financial statements adequately present, in all material respects, the equity and financial position of Glenmark Farmacêutica Ltda. on March 31, 2021, the performance of its operations and its cash flows for the year ended on that date, in accordance with Brazilian and international accounting practices.

The financial statements presented are not intended to be a complete presentation of the operating results and financial position of Glenmark Farmacêutica Ltda. and does not contain all required informational disclosures.

Restriction on Use and Distribution

These financial statements have been prepared for the purpose of providing information to the Glenmark Group to enable it to prepare the group's consolidated financial statements. As a result, the financial statements are not a complete set of financial statements for Glenmark Farmacêutica Ltda. in accordance with Brazilian and international accounting practices and is not intended to fairly present, in all material in this regard, the financial position of Glenmark Farmacêutica Ltda. as of March 31, 2021, either the results of its operations, or its cash flows for the year then ended in accordance with these financial reporting frameworks. Financial information for special purposes may therefore not be suitable for other purposes.

This report is intended solely for the information and management use of Glenmark Farmacêutica and Glenmark Group and Suresh Surana & Associates LLP and should not be used by anyone other than those specified parties.

BOUCINHAS, CAMPOS CONTI Auditores Independentes S/S CRC 2SP 5.528/0-2

João Paulo Antonio Pompeo Conti

Contador

CRC 1SP057611/O-0

Glenmark Farmaceutica Ltda.

INR in Mn

		· · · · · · · · · · · · · · · · · · ·			INR in Mn
Statement of Financial Position	Sch	March 31, 2021	March 31, 2020	March 31, 2021	March 31, 2020
A COTOTO					
ASSETS Non current assets					
	S 1	27.864.590	30.040.096	357	432
Property, plant and equipment Goodwill	S 2 A	3.052.784	3.052.784	39	432
Other Intangible Assets	S 2 B	1.510.750	1.545.784	19	22
Investments accounted for using the equity method	S 3	1.510.750	1.545.764	19	
Long term financial assets	S 4		-		
Deferred tax assets	S 3	129.831.728	105.187.505	1.662	1.513
Restricted cash	S 6	-	-	-	-
Total non- current assets		162.259.852	139.826.169	2.077	2.011
Inventories	S 4	28.911.517	30.982.283	370	446
Trade receivables	S 5	51.297.993	54.516.813	657	784
Unbilled revenue	S 9	31.277.993	JT.J10.01J	-	704
Derivative financial instruments	S 10	[_ [-		_
Short term investment	S 11	_	_	_	_
Other short-term financial assets	S 6	10.596.683	7.020.713	136	101
Investmet in Other Company		-	5.024.737		
Current tax assets	S 7	18.967.689	17.261.028	243	248
Cash and cash equivalents	S 8	7.517.776	14.836.642	96	213
Restricted cash	S 6	-	-	_	-
Total current assets		117.291.658	129.642.216	1.501	1.864
Assets and disposal group classified as held for sale	S 15	-	-	-	-
Total assets		279.551.510	269.468.385	3.578	3.875
				-	-
EQUITY AND LIABILITIES				-	-
Equity				-	-
Equity attributable to owners of the parent:		405 404 450	105 101 150		-
Share capital		485.696.178	485.696.178	6.984	6.984
APIC/ Share Premium			-		- (4.050)
Retained earnings		(351.197.522)	(302.699.517)	(4.495)	(4.353)
Reserves & Surplus		-	-	(466)	3.196
Currency translation reserve		-	-	(400)	5.190
Non Controlling Interest		_	_	_	_
Total Equity		134.498.656	182.996.661	1.722	2.631
Liabilities				-	-
Current liabilities				-	-
Provisions	S 9	1.095.070	5.472.321	14	79
Trade payables	S 10	136.410.153	73.817.698	1.746	1.061
Other current liabilities	S 11	7.547.631	7.181.704	97	103
Current portion of borrowings		_	-	-	-
Current tax liabilities		-	-	-	-
Total current liabilities		145.052.854	86.471.723	1.857	1.243
Liabilities included in disposal group held for sale		-	-	-	-
Total liabilities		145.052.854	86.471.723	1.857	1.243
Total equity and liabilities		279.551.510	269.468.384	3.578	3.874
* *		'		·	

 $(The\ accompanying\ notes\ form\ an\ integral\ part\ of\ these\ financial\ statements)$

Difference check

For identification

Glenmark Farmaceutica Ltda.

Amt in BRL

INR in Mn

Statement of Comprehensive Income Sch March 31, 2021 March 31, 2020 March 31, 2021	March 31, 2020
Income from operations 144.852.856 188.418.305 1.98 Other income \$16 17.773.862 9.841.427 24 - - - - Total 162.626.718 198.259.732 2.23 Cost of materials \$12 160.060.305 130.111.045 2.15 Employee benefit expenses \$13 35.469.159 40.256.356 48 Depreciation, amortisation and impairment of non-financial assets \$1/\$\$S\$ 2 2.557.809 6.082.022 3 S26 - - - - - Other expenses \$14 \$1.661.735 \$3.219.045 70 Total 249.749.008 229.668.468 3.42	
Other income \$16 17.773.862 9.841.427 24 Total 162.626.718 198.259.732 2.23 Cost of materials \$ 12 160.060.305 130.111.045 2.19 Employee benefit expenses \$ 13 35.469.159 40.256.356 48 Depreciation, amortisation and impairment of non-financial assets \$1/\$ 2 2.557.809 6.082.022 3 S26 - - - - - Other expenses \$ 14 \$ 1.661.735 \$ 53.219.045 70 Total 249.749.008 229.668.468 3.42	
Other income \$16 17.773.862 9.841.427 24 Total 162.626.718 198.259.732 2.23 Cost of materials \$ 12 160.060.305 130.111.045 2.19 Employee benefit expenses \$ 13 35.469.159 40.256.356 48 Depreciation, amortisation and impairment of non-financial assets \$1/\$ 2 2.557.809 6.082.022 3 S26 - - - - - Other expenses \$ 14 \$ 1.661.735 \$ 53.219.045 70 Total 249.749.008 229.668.468 3.42	
Total 162.626.718 198.259.732 2.23 Cost of materials S 12 160.060.305 130.111.045 2.15 Employee benefit expenses S 13 35.469.159 40.256.356 48 Depreciation, amortisation and impairment of non-financial assets S1/S 2 2.557.809 6.082.022 3 Cother expenses S 14 51.661.735 53.219.045 70 Total 249.749.008 229.668.468 3.42	
Cost of materials Employee benefit expenses Employee benefit expenses Depreciation, amortisation and impairment of non-financial assets S1/S 2 S26 Other expenses S14 S14 S1.661.735 S3.219.045 Total Cost of materials S12 S160.060.305 S13 S1.660.735 S1.660.735 S1.760 S	170
Cost of materials Employee benefit expenses Employee benefit expenses Depreciation, amortisation and impairment of non-financial assets S1/S 2 S26 Other expenses S14 S14 S1.661.735 S3.219.045 Total Cost of materials S12 S160.060.305 S13 S1.660.735 S1.660.735 S1.760 S	-
Cost of materials Employee benefit expenses Employee benefit expenses Depreciation, amortisation and impairment of non-financial assets S1/S 2 S26 Other expenses S14 S14 S1.661.735 S3.219.045 Total Cost of materials S12 S160.060.305 S13 S1.660.735 S1.660.735 S1.760 S	2.851
Employee benefit expenses S 13 35.469.159 40.256.356 48 Depreciation, amortisation and impairment of non-financial assets S1/S 2 2.557.809 6.082.022 3 Other expenses S 14 51.661.735 53.219.045 70 Total 249.749.008 229.668.468 3.42	
Employee benefit expenses S 13 35.469.159 40.256.356 48	2.244
S26 S 14 51.661.735 53.219.045 70 Total 249.749.008 229.668.468 3.42	
Other expenses \$ 14 51.661.735 53.219.045 70 Total 249.749.008 229.668.468 3.42	105
Total - 249.749.008 229.668.468 3.42	-
Total 249.749.008 229.668.468 3.42	918
-	-
Operating profit (87.122.290) (31.408.736) (1.19	3.303
Operating profit (8/.122.290) (31.408./36) (1.15	-
	(542)
Share of profit from equity accounted investments	_
Finance costs S17 12.015.846 5.658.581 10	
Finance income S 28	_
Other financial expenses	_
Non Operative Income S20 25.995.908 - 35	_
Profit/(Loss) before tax (73.142.228) (37.067.317) (1.00	(639)
	-
Income tax (expense)/credit S15 (24.644.223) (8.427.974) (33	(145)
-	-
Profit/(Loss) after tax from continuing operations (48.498.005) (28.639.343)	(494)
	-
Post tax profit/ (loss) for the year from discontinued operations	-
Profit/(Loss) after tax carried to balance sheet (48.498.005) (28.639.343) (66	(494)
(40.470.003) after tax carried to balance sheet	' (194)
Profit for the year attributable to:	
Non Controlling Interest	
Owners of the parent	

For identification

Amt in BRL INR in Mn

	,			
Particulars	March 31, 2021	March 30, 2020	March 31, 2021	March 30, 2020
(A) Cash flow from operating activities				
Profit before tax	(73.142.228)	(37.067.317)	(936)	(533)
Adjustments for non cash items:			-	-
Amortization			-	-
Depreciation	2.557.809	6.265.160	33	90
Impairment of goodwill	-	-	-	-
Rent (unwinding of prepayments arisen on discounting long term security deposits at fair value)		<u>-</u>		-
Interest expenses	12.015.846	5.658.581	165	98
Unrealised gain on exchange fluctuation	-	-	-	-
Dividend income	-	-	-	-
	-	-	-	-
Loss from the sale of property, plant and equipment	-	-	-	-
Profit from the sale of short term investments	-	-	-	-
Unclaimed balances and provisions written back	-	-	-	-
Provision for doubtful debts			-	-
Profit / Loss on sale of assets	97.387	(362.203)	1	(5)
Cash flows from operations before changes in working capital	(58.471.186)	(25.505.779)	(748)	(367)
Changes in operating assets and liabilities				-
Non current liabilities, trade payables and other current liabilities	(2.847.748)	39.338.051	(36)	566
Inter-company Liablities	61.428.879	18.480.686	786	266
Long term financial assets	-		-	
Trade receivables and unbilled revenue	1.213.810	(16.464.253)	16	(137)
inter-company receivables	2.005.010	(3.494.024)	26	(1)
Other current assets	1.812.872	(11.355.756)	23	(163)
Taxes paid	-		-	-
Net cash generated from operating activities	63.612.823	26.504.704	814	381
				-
(B) Cash flow from investing activities				-
Purchase of property, plant and equipment	(896.065)	(1.037.208)	(11)	(15)
Purchase of other intangible assets	(183.138)	(501.482)	(2)	(7)
Proceeds from sale of property, plant and equipment	634.546	4.911.407	8	71
Net proceeds from the sale of short term investments	-	-	-	-
Net cash outflow on acquisition of subsidiary (refer note)	-	-	-	-
Net cash outflow in mutual funds and others	-		-	-
Movement in restricted cash	-	-	-	-
Net cash flow on disposal of subsidiary (refer note)		-		-
Interest received	-		-	-
Dividend received	-		-	-
Net cash generated from/ (used in) investing activities	(444.657)	3.372.717	(6)	48
				-
(C) Cash flows from financing activities				-
Proceeds from issue of shares	-	6.172.418		89
Repayment of borrowings	-			
Interest paid on borrowings	(12.015.846)	(5.658.581)	(165)	(98)
Dividends paid	-		-	-
Unrealised gain on exchange fluctuation	-		-	-
Net cash (used in)/ generated from financing activities	(12.015.846)	513.837	(154)	7
				-
Net change in cash and cash equivalents from continuing operations	(7.318.866)	4.885.479	(94)	70
FCTR Adjustments			(16)	10
Net cash flows from discontinued operations	-		- '1	-
Net change in cash and cash equivalents	(7.318.866)	4.885.479	(110)	80
Cash and cash equivalents at the beginning of the year	14.836.642	9.951.163	213	176
Cash and cash equivalents acquired on merger				-
Effect of change in exchange rate on cash and cash equivalents included in disposal group				_
Cash and cash equivalents at the end of the year	7.517.776	14.836.642	96	213
and the few	7.517.770	11.050.042	- 70	213

(The accompanying notes are an integral part of these consolidated financial statements)

Guilherme Cruz T da Cunha Boucinhas, Campos & Conti

For identification

Statement of Comprehensive Income	Sch	March 31, 2021	March 31, 2020
Profit for the year		(48.498.005)	(28.639.343)
Other comprehensive income:			
Exchange differences on translating foreign operations	-	-	-
Other comprehensive income for the period, net of tax		-	-
Total comprehensive income for the period		(48.498.005)	(28.639.343)
Total Comprehensive Income attributable to: Non Controlling Interest Owners of the parent		(48.498.005)	(28.639.343)

4)
-
-
-
-
-
_
_
1)
_
4)

For i

Guilherme Cruz T da Cunha

Boucinhas, Campos & Conti

Amt In BRL

Particulars	March 31, 2021	March 31, 2019
Investment Other Company Glenmark Cosmetico - Projeto Hypera	-	5.024.737
		-
Total Investment Other Company	-	5.024.737

INR in Mn

Particulars	March 31, 2021	March 31, 2019
Investment Other Company	_	
Glenmark Cosmetico - Projeto Hypera	_	93
	-	
	-	
	-	
Total Investment Other Company	-	93

For identification

Guilherme Cruz T da Cunha

Boucinhas, Campos & Conti

Other intangible assets

The Group's other intangible assets comprises of acquired computer softwares, website costs and softwares under development. The carrying amounts for the reporting periods under review are analysed as follows:

Amt In BRL

Particulars	Computer software	Brands	Total
Cost			
Balance as at March 31, 2020	859.640	93.090.744	93.950.384
- Internally developed	-	-	-
- Acquired through business combinations	-	-	-
- Other acquisitions	183.138	-	183.138
- Disposals/ Transfers	-	-	-
- Translation adjustment	-	-	-
Balance as at March 31, 2021	1.042.778	93.090.744	94.133.522
Amortisation and impairment			
Balance as at March 31, 2020		92.404.600	92.404.600
- Amortisation charge for the year	-	-	-
- Amortisation / Impairment for the year	124.560	93.612	218.172
- Amotisation charge for dosposals/ transfers		-	-
- Translation adjustment	-	-	-
Balance as at March 31, 2021	124.560	92.498.212	92.622.772

Carrying value

Balance as at March 31, 2020	859.640	686.144	1.545.784
Balance as at March 31, 2021	918.218	592.532	1.510.750
	918.218	592.532	

INR in Mn

Particulars	Computer software	Brands	Total
Cost			
Balance as at March 31, 2020	94	1.891	1.985
- Internally developed	-	-	-
- Acquired through business combinations	-	-	-
- Other acquisitions	3	-	3
- Disposals/ Transfers	-	-	-
- Translation adjustment	(82)	(552)	(634)
Balance as at March 31, 2021	15	1.339	1.354
	0	-	
Amortisation and impairment	-	-	-
Balance as at March 31, 2020	69	1.744	1.814
- Amortisation charge for the year	-	-	-
- Amortisation / Impairment for the year	2	1	3
- Amotisation charge for dosposals/ transfers	-	-	-
- Translation adjustment	(69)	(415)	(485)
Balance as at March 31, 2021	2	1.330	1.332

Carrying value

Surrying value			
Balance as at March 31, 2020	25	147	172
Balance as at March 31, 2021	13	9	22

For identification

Deferred taxes arising from temporary differences and unused tax losses are summarized as follows:

Amt In BRL

		3.5 . 4.4 . 4.4	D : 1	77 1.2	
		March 31, 2020	Recognised	Translation	March 31, 2021
			in profit and loss	adjustment	
			account		
	Particulars				
Deferred tax assets	-				
	Intangible assets			-	
	Property, plants and equipments			-	
	Retirement benefits and other employee benefits			-	
	Straight lining of rent			-	
	Minimum Alternative Tax credit entitlement			-	
İ	Impact of change on tax rates from previous year			_	
	Unused tax losses	105.187.505	24.644.223	_	129.831.728
	Others		-	-	
	Total	105.187.505	24.644.223	-	129.831.728
Deferred tax liabilities					
Deferred that hapmines	Intangible assets			_	
	Other current assets				
	Total			_	
	Total	-	-	-	-
Net deferred tax asset		105.187.505	24.644.223	-	129.831.728

INR in Mn

		March 31, 2020	Recognised	Translation	March 31, 2021
			in profit and loss	adjustment	
			account		
	Particulars				
Deferred tax assets					
	Intangible assets	-	-	-	-
	Property, plants and equipments	-	-	-	-
	Retirement benefits and other employee benefits	-	-	-	-
	Straight lining of rent	-	-	-	-
	Minimum Alternative Tax credit entitlement	-	-	-	-
	Impact of change on tax rates from previous year	-	-	-	-
	Unused tax losses	1.897	338	(368)	1.867
	Others	-	-	-	-
	Total	1.921	354	(408)	1.867
		-	-		-
Deferred tax liabilities		-	-	-	-
	Intangible assets	-	-	-	-
	Other current assets	-	-	-	-
	Total	-	-	-	-
		-	-	-	-
Net deferred tax asset		1.897	354	(384)	1.867

For identification

S 4 Inventories

Inventories recognised in the statement of financial position can be analysed as follows:

Amt In BRL

Particulars	March 31, 2021	March 31, 2020
Raw Materials	151.604	163.251
Packing Material	-	55.961
Work-in-Process	(2)	7.711
Finished Goods	28.759.915	30.755.360
Total	28.911.517	30.982.283

T > TT	٠.		
INI	₹ 1n	M	n

March 31, 2021	March 31, 2020
2	2
-	1
-	-
368	442
-	-
-	-
-	-
370	446

In the year ending 31 March 2011, a total of INR___ of inventories was included in profit and loss as an expense (2010: INR___). This includes an amount of INR___ resulting from write down of inventories (2010: INR___).

For identification

S 5

Trade receivables

The carrying amount of trade receivables are analysed as follows:

Amt In BRL

INR in Mn

Particulars	March 31, 2021	March 31, 2020	
Gross value			
Receivables	53.203.499	55.519.886	
Less: Allowance for credit losses	1.905.506	1.003.073	
Net trade receivables	51.297.993	54.516.813	

March 31, 2021	March 31, 2020
681	798
24	14
657	784

For identification

S 6 Other short term financial assets

Amt In BRL

Particulars	March 31, 2021	March 31, 2020
Advance tax and tax deducted at source(net of provision for current taxes)	587.994	578.447
Short term - deposit	3.768.499	3.676.363
Advance to Vendors	5.336.123	2.098.812
Others	904.067	667.091
Total	10.596.683	7.020.713

INR in Mn

		11 111 111 1111
Particulars	March 31, 2021	March 31, 2020
Advance tax and tax deducted at source(net of provision for current taxes)	8	8
Short term - deposit	-	53
Advance to Vendors	68	30
Others	12	10
Total	136	101

For identification

S 7 Current tax assets

Amt In BRL

IN	R	in	Mn

Particulars	March 31, 2021	March 31, 2020
Input Taxes Receivable	18.967.689	17.261.028
Total	18.967.689	17.261.028

11 (11 111 1/111		
March 31, 2021	March 31, 2020	
243	248	
243	248	

For identification

Guilherme Cruz T da Cunha

Boucinhas, Campos & Conti

S 8 Cash and cash equivalents

Cash and cash equivalents include the components as follows:

Amt In BRL

Particulars	March 31, 2021	March 31, 2020
Cash on hand	6.343	6.345
Cheques in hand	-	-
Cash in current accounts	7.511.433	14.830.297
Total	7.517.776	14.836.642

INR in Mn

Particulars	March 31, 2021	March 31, 2020
Cash on hand	-	-
Cheques in hand	-	-
Cash in current accounts	96	176
Cash in deposit accounts	-	-
Mutual fund deposit in liquid money market	-	-
Fund-in-transit	-	-
Total	96	213

For identification

S-9

Provisions

All provisions are considered current. The carrying amounts may be analysed as follows:

Amt In BRL

Particulars	
Carrying amount on March 31, 2020	5.472.321
Additional provisions	1.095.070
Amount utilised	5.472.321
Reversals	
Carrying amount on March 31, 2021	1.095.070

INR in Mn

Particulars	
Carrying amount on March 31, 2020	64
Additional provisions	16
Amount utilised	79
Reversals	-
Carrying amount on March 31, 2021	16

For identification

Schedule - S 3 Schedule - S 10

Trade payables		Amt In BRL
Particulars	March 31, 2021	March 31, 2020
Sundry creditors		
Foreign Creditors	112.744.073	52.379.041
Local Creditors	23.666.080	21.438.657
Total	136.410.153	73.817.698

INR in Mn

March 31, 2021	March 31, 2020
1.443	753
303	308
-	-
-	-
-	-
1.746	1.061

For identification

S 11 Other current liabilities

Other current liabilities are summarized as follows:

	-	DDT	
Amt	10	RRI	
/ MIII	111	10101	

TA III		3.5
INR	111	Mh
11 / 11/	. 111	TATT

Particulars	March 31, 2021	March 31, 2020	
Employee dues	3.214.723	2.905.614	
Statutory dues	1.909.358	2.932.654	
Others	2.423.550	1.343.436	
Total	7.547.631	7.181.704	

	11 (11 111 17111
March 31, 2021	March 31, 2020
41	42
24	42
31	19
-	-
97	103

For identification

S 16

Total

Other income

Other income is summarised as follows:

	March 31, 2021	March 31, 2020
Profit on sale of fixed assets	781.013	807.079
Exchange Gain	16.569.815	9.118.726
Miscellaneous income	423.034	(84.378)

March 31, 2021	March 31, 2020
11	12
227	131
6	(1)
-	-

244

INR in Mn

For identification

Amt In BRL

9.841.427

17.773.862

S 17 Finance income and finance costs

1.1 Finance income

Finance income is analysed as follows:

Thinke moone is many see as follows:		Amt In BRL
Particulars	March 31, 2021	March 31, 2019
Interest income on		
Inter company balances		
Fixed deposits		
Fair valuation of financial assets and liabilities		
Interest on security deposits for operating leases		
Total	-	

	INR in Mn
March 31, 2021	March 31, 2019
-	-
-	-
-	-
-	-
-	-

1.2 Finance costs

Particulars	March 31, 2021	March 31, 2020
Borrowings recognised at amortised cost:		
- Interest expense on short term borrowings		
Term loans		
Cash credit		
Others	8.876.497	5.087.670
- Bank charges	3.139.349	570.911
Total	12.015.846	5.658.581

March 31, 2018	
-	
-	
-	
73	
8	
81	

For identification

S 18 Equity

1.1 Share capital

The share capital of 479.523.760, Glenmark Holding S.A with 479.523.760 shares and Glenmark Pharmaceuticals S.A with 1 share, consists of only of fully paid ordinary shares with a par value of R\$ 1/per share. The total number of authorised shares of the company as on each statement of financial position date is summarized as follows:

Amt In BRL

Particulars	March 31, 2021	March 31, 2020
Total number of authorised shares Shares issued and fully paid up	485.696.178	485.696.178
Beginning of the year	485.696.178	479.523.760
Issued under share-based payments	-	-
Share issue	-	6.172.418
Shares issued and fully paid	485.696.178	485.696.178

INR in Mn

Particulars	March 31, 2021	March 31, 2020
Total number of authorised shares	6.217	6.984
Shares issued and fully paid up	-	-
Beginning of the year	6.984	8.467
Issued under share-based payments	=	-
Share issue	-	89
Shares issued and fully paid	6.217	6.984

For identification

1 Financial assets and liabilities

Fair value or carrying amounts of assets and liabilities presented in the statement of financial position relates to the following categories of assets and liabilities:

Amt In BRL

INR in Mn

Financial Assets	March 31, 2021	March 31, 2020
Non-current assets		
Held to maturity investments		
- Equity and preference shares		
Available for sale financial assets		
- Debentures		
Loans and receivables		
-Security deposits for operating leases and others		
services		
- Restricted cash		
Current assets		
Loans and receivables		
-Trade receivables	51.297.993	54.516.813
- Other current assets *	58.475.889	55.264.024
- Cash and cash equivalents*	-	-
Financial assets held for trading (carried at fair value through		
profit or loss)		
- Short term investments		
Total	109.773.882	109.780.837

	INK in Mn
March 31, 2021	March 31, 2020
-	-
-	-
-	-
_	_
	_
	_
-	
-	1
-	-
-	-
-	
657	784
748	795
-	-
-	-
-	-
1.405	1.579

Financial Liabilities	March 31, 2021	March 31, 2019
Non current liabilities		
Financial liabilities measured at amortised cost:		
- Borrowings from related parties		
- Other liabilities		
Current liabilities		
Financial liabilities measured at amortised cost:		
- Trade payables *	136.410.153	73.817.698
- Other current liabilities *	8.642.701	12.654.025
- Current portion of borrowings from related		
parties		
- Other borrowings		
- Current tax liabilities		
Total	145.052.854	30.919.691

March 31, 2021	March 31, 2017	
_	_	
-		
-	-	
-	-	
-	-	
-	-	
1.746	1.061	
111	182	
-	-	
_	_	
	_	
1 057	115	
1.857	445	

For identification

^{*} These financial assets and liabilities have been recorded at their respective carrying amounts as the management considers the fair values to be not materially different from their carrying amounts recognized in the statement of financial positions as these are expected to realize within one year from the statement of financial position dates.

S 20 Non Operative Income

Amt In BRL

	March 31, 2021	March 31, 2020
Exceptional item	25.995.908	
Total	25.995.908	-

INR in Mn

March 31, 2021	March 31, 2020
356	-
-	-
-	-
356	-

For identification

Property, plant and equipment The Group's property, plant and equipment comprise freehold and leasehold land, IT and office equipment, and furniture and fixture. The carrying amount are analysed as follows: ok ok Amt In BRL Other Equipment Factory Plant & Furniture Vehicles AS11 Fixed Capital Total Building Building Machinery and fixture asset work in progress Particulars 1.926.619 14.322.542 3.077.398 38.828.241 6.414.572 735.461 1.551.972 10.799.677 Balance as at March 31, 2020 - Acquisitions through business combinations 340.176 - Other acquisitions 25.000 530.889 896.065 - Disposals/Transfers 70.261 2.235.382 2.305.643 - Translation adjustment 14.322.542 11.330.566 37.418.663 Balance as at March 31, 2021 1.926.619 6.369.311 735.461 1.892.148 842.016 Accumulated Depreciation 824.999 3.806.057 1.881.346 156.882 1.040.937 1.077.924 Balance as at March 31, 2020 8.788.145 - Depreciation charge for the year 173.637 860.762 578.809 59.504 195.986 483.303 2.352.001 - Impairment loss recognized 4.099 1.581.975 1.586.074 - Disposals/Transfers - Translation adjustment (20.748) 998.636 4.666.819 2.456.056 216.386 1.236.923 9.554.072 Balance as at March 31, 2021 -Carrying value At March 31, 2020 1.101.620 10.516.485 4.533.226 578.579 511.035 1.999.474 10.799.677 30.040.096 927.983 9.655.723 3.913.255 519.075 655.225 862.764 11.330.566 27.864.591 At March 31, 2021 ok ok 927.982 862.764 11.330.566 9.655.723 3.913.255 519.075 655.225 S 1 INR in Mn Factory Other Plant & Furniture Equipment Vehicles AS11 Fixed Capital Total Building Building Machinery and fixture work in progress Particulars Balance as at March 31, 2020 28 206 92 11 22 44 155 558 - Acquisitions through business combinations - Other acquisitions 5 12 32 - Disposals/Transfers 31 (123)- Translation adjustment (3) (23)(11)(2) (64)(17)Balance as at March 31, 2021 25 183 82 9 24,22 11 _ 145 479 Accumulated Depreciation 12 55 27 126 Balance as at March 31, 2020 2 15 16 - Depreciation charge for the year 2 12 32 3 - Impairment loss recognized 22 22 - Disposals/Transfers (1) (7) (4) (2) (45)(58)- Translation adjustment Balance as at March 31, 2021 13 60 31 3 16 122

Carrying value At March 31, 2020 155 432 16 151 65 28 357 12 51 At March 31, 2021 123 11 145

> For identification quiling lage & the

S 2 A

Goodwill

Goodwill appearing as on April 1, 2011 is in relation to business combinations done prior to the transition date. Company has availed exemption under IFRS 1 in respect of such business combinations.

The net carrying amount of goodwill can be analysed as follows:

Amt In BRL

INR in Mn

Particulars	March 31, 2021	March 31, 2020
Gross carrying amount		
Balance as on April 1	6.516.141	6.516.141
Acquired through business combination	-	-
Accumulated depreciation	3.463.357	3.463.357
Disposals/ Transfers	-	-
Translation adjustment	-	-
Balance as at March 31, 2021	3.052.784	3.052.784
Accumulated impairment		
Balance as on April 1	3.463.357	3.463.357
Impairment loss recognised		
Translation adjustment	-	-
Balance as at March 31, 2021	3.463.357	3.463.357
Carrying amount at	3.052.784	3.052.784

	INR in Mn
March 31, 2021	March 31, 2020
128	94
-	-
68	50
-	-
(21)	-
39	44
-	-
-	-
68	50
-	-
(24)	-
44	50
-	-
39	44

3.052.784

For identification

Schedule - S 12 Cost of materials

Cost of materials		Amt In BRL
Particulars	March 31, 2021	March 31, 2020
Consumption of Raw and Packing material		
Opening Stock	219.212	219.212
Less: Sales	67.608	-
Less: Closing stock	151.604	219.212
Finished goods purchased	137.109.231	118.429.697
Other Charges	20.812.700	18.903.082
(Increase)/Decrease in Stock of Finished goods/WIP		
Opening Stock		
-Work in progress	7.711	7.71
-Finished goods	30.755.360	23.533.620
Less: Closing Stock	-	-
-Work in progress	(2)	7.711
-Finished goods	28.759.915	30.755.360
Total	160.060.305	130.111.045

INR in Mn

March 31, 2021	March 31, 2020
3	3
3	=
2	3
-	=
1.880	1.703
285	272
_	-
-	-
_	-
_	_
422	338
_	_
_	_
_	_
394	442
_	_
-	_
2.194	1.871

Schedule - 13 Employee benefit expenses

Employee benefit expenses		
Particulars	March 31, 2021	March 31, 2020
Salaries and bonus	33.711.372	37.517.347
Staff welfare expenses	1.757.787	2.739.009
Total	35.469.159	40.256.356

March 31, 2021	March 31, 2020
462	539
24	39
196	570

Schedule - S 14 Other expenses

Particulars	March 31, 2021	March 31, 2020
Sales Promotion Expenses	4.975.084	9.824.843
Travelling Expenses	1.141.392	3.447.288
Freight Outward Expenses	6.454.401	7.576.493
Telephone Expenses	339.068	398.711
Rates and Taxes	351.883	469.139
Insurance Expenses	4.415	27.780
Electricity Charges	150.393	143.826
Rent	2.688.869	2.164.429
Repaires and Maintenance	1.206.013	999.505
Legal and Professional Fees	2.487.100	3.217.328
Exchange Loss	21.812.299	18.407.279
Audit Fee	74.927	70.347
Other Operating Expenses	9.975.891	6.472.077
Total	51.661.735	53.219.045

March 31, 2021	March 31, 2020
68	141
16	50
88	109
5	6
5	7
-	-
2	2
37	31
17	14
34	46
299	265
1	1
137	93
-	-
708	765

Schedule - S15 Income tax (ex

ense)/credit

Particulars	March 31, 2021	March 31, 2020	
Current income tax MAT Credit Deferred tax Prior period tax Wealth tax	(24.644.223)	(8.427.974)	
Total	(24.644.223)	(8.427.974)	

March 31, 2021	March 31, 2020
-	-
=	=
(338)	(121)
-	-
-	-
=	=
(338)	(121)

For identification

Guilherme Cruz T da Cunha
Bonciologo Como Como Boucinhas, Campos & Conti

Glenmark Farmaceutica Ltda.

Statement of Cash Flows

Amt in BRL INR in Mn

Particulars	M	M 1- 21 2020	March 31, 2021	M1-21 2020
(A) Cash flow from operating activities	March 31, 2021	March 31, 2020	March 31, 2021	March 31, 2020
Profit before tax	(73.142.228)	(37.067.317)	(936)	(533)
Adjustments for non cash items:	(/3.142.220)	(37.007.317)	(930)	(333)
Amortization			-	-
Depreciation	2,557,809	6,265,160	33	90
Impairment of goodwill	2.337.009	0.203.100	33	90
impairment of goodwiii	-	-	-	-
Rent (unwinding of prepayments arisen on discounting long term security deposits				
at fair value)	-	-	-	-
Interest expenses	12.015.846	5.658.581	165	81
Profit / Loss on sale of assets	97.387	(362.203)	1	(5)
Cash flows from operations before changes in working capital	(58.471.186)	(25.505.779)	(748)	(367)
Changes in operating assets and liabilities			-	-
Non current liabilities, trade payables and other current liabilities	58.581.131	57.818.737	750	831
Long term financial assets	-	-	-	-
Trade receivables and unbilled revenue	3.218.820	(19.958.277)	41	(287)
Other current assets	1.812.872	(11.355.756)	23	(163)
Taxes paid	-	-	-	-
Net cash generated from operating activities	63.612.823	26.504.704	814	381
(B) Cash flow from investing activities				-
Purchase of property, plant and equipment	(896.065)	(1.037.208)	(11)	(15)
Purchase of other intangible assets	(183.138)	(501.482)	(2)	(7)
Proceeds from sale of property, plant and equipment	634.546	4.911.407	8	71
Net cash generated from/ (used in) investing activities	(444.657)	3.372.717	(6)	48
			=	-
(C) Cash flows from financing activities			-	-
Proceeds from issue of shares	-	6.172.418	-	89
Repayment of borrowings	-	-	-	-
Interest paid on borrowings	(12.015.846)	(5.658.581)	(165)	(81)
Net cash (used in)/ generated from financing activities	(12.015.846)	513.837	(154)	7
Net change in cash and cash equivalents from continuing operations	(7.318.866)	4.885.479	(94)	70
FCTR Adjustments	(7.510.000)	4.005.477	(16)	70
Net cash flows from discontinued operations	_	_	(10)	
Net change in cash and cash equivalents	(7.318.866)	4.885.479	(110)	70
Cash and cash equivalents at the beginning of the year	14.836.642	9.951.163	213,35	143
Cash and cash equivalents at the beginning of the year Cash and cash equivalents acquired on merger	14.030.042	7.751.105	213,33	143
Effect of change in exchange rate on cash and cash equivalents included in	-	-		-
Cash and cash equivalents at the end of the year	7.517.776	14.836.642	96	213
Cash and Cash equivalents at the end of the year	7.517.770	17.050.042	90	213

(The accompanying notes are an integral part of these consolidated financial statements)

For identification

Glenmark Farmaceutica Ltda. Statement of Changes in Equity

[All amounts are stated in Brazilian Real, unless otherwise stated]

Particulars	Share Capital	Retained earnings	Capital Reserve	Employee compensation reserve	Exchange fluctuation reserve	Foreign Currency monetary translation reserve	General reserve	Total equity
Balance as at March 31, 2020	485.696.178	(302.699.517)	-	-	-	-	-	182.996.661
Dividends								-
Dividend tax								-
Residual Dividend and Dividend Tax								-
Profit for the year		(48.498.005)						(48.498.005)
Total comprehensive income for the year								-
Balance as at March 31, 2021	485.696.178	(351.197.522)	-	-	-	-	-	134.498.656

(The accompanying notes are an integral part of these consolidated financial statements)

INR in Mn

								11 (10 111 11111
Particulars	Share Capital	Retained earnings	Capital Reserve	Employee compensation reserve	Exchange fluctuation reserve	Foreign Currency monetary translation reserve	General reserve	Total equity
Balance as at March 31, 2020	8.576	(4.353)	-	-	-	-	-	2.631
Income tax relating to components of other comprehensive							-	
income	-	-	-	-	-	-		-
- Translation adjustment	(1.592)	(142)	-	-	-	-	-	(1.734)
Total comprehensive income for the year	-	-	-	-	-	-	-	_
Balance as at March 31, 2021	6.984	(4.495)	-	-	-	-	-	1.722

For identification

IFRS Reporting Pack	
Entity:	Glenmark Farmaceutica Ltda
Country:	Brazil
Year:	31/mar/21
Local Currency	BRL
Currency	INR
Prepared by	Heraldo Batista
Reviewed by	

Reporting Period March 31, 2021 Comparative Period March 31, 2020 For identification

Guilherme Cruz T da Cunha Boucinhas, Campos & Conti

Closing Rate 12,8000 clg Average Rate 13,7100 avg

PY Closing Rate
PY Average Rate
14,3800 cclg
17,2500 cavg